Once a day Trientine
PreclinicalSmall molecule
Once a day Trientine is one of 8 small molecule programs targeting Wilson disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Wilson Disease
#DrugCompanyPhaseTrials
1Zinc Acetate
NNobelpharma
Approved
Tetrathiomolybdate
UUniversity of Michigan Rogel Cancer Center
Phase 3
Trientine Dihydrochloride
UUnivar BV
Approved
Soc Therapy
AstraZenecaPhase 3
Syprine
BBausch Health Americas, Inc.
Phase 3
ALXN1840
AstraZenecaPhase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
Once a day Trientine
YYale University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Once a day Trientine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYale University